Navigation Links
Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
Date:8/7/2013

LAVAL, Quebec, Aug. 7, 2013 /PRNewswire/ --

  • Total Revenue $1.1 billion; an increase of 41% over the prior year, excluding one-time items in 2012 second quarter
  • Product Sales $1.06 billion; an increase of 43% over the prior year
  • 4% organic growth (same store sales) for the Developed Markets segment, excluding the impact from Zovirax Ointment
  • 5% organic growth (same store sales) for Developed Markets segment, excluding the impact from Zovirax Franchise
  • 14% organic growth (same store sales) for the Emerging Markets segment
  • GAAP EPS $0.03; Cash EPS $1.34, an increase of 54% over the prior year, excluding one-time items in 2012 second quarter
  • GAAP Operating Cash Flow $305 million; Adjusted Operating Cash Flow $423 million; an increase of 61% over the prior year excluding one-time items in 2012 second quarter
  • Bausch + Lomb acquisition closed August 5, 2013 and Valeant expects to realize significantly more than $800 million in synergies
  • 2013 Guidance for Cash EPS raised to $6.00 to $6.20, from $5.55 to $5.85, and includes;
  • Negative impact of $0.11 from pre-closing interest expense and additional share count associated with the Bausch + Lomb financing
  • Negative impact of $0.06 from foreign exchange movement
  • Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces second quarter financial results for 2013.

    "The continued outperformance of our businesses, which delivered strong financial results and organic growth despite the genericization of our largest product in April, demonstrates the value of a diversified portfolio," stated J. Michael Pearson, chairman and chief executive officer.  "We are particularly pleased with the performance of our Emerging Markets segment, which delivered organic growth of 14%."

    "In addition to focusing on mana
    '/>"/>

    SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

    Related medicine technology :

    1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
    2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
    3. Valeant Pharmaceuticals To Host Investor Day
    4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
    5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
    6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
    7. Valeant Pharmaceuticals Announces Management Change
    8. Valeant Pharmaceuticals To Syndicate Incremental Loans
    9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
    10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
    11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... De Pfizer Clinical Research Unit (PCRU) heeft ... van Japanse komaf voor medewerking aan klinisch onderzoek. De ... één van twee onderzoekseenheden van Pfizer , een ... door de ontdekking en ontwikkeling van nieuwe medicijnen. Om ... mannen en vrouwen van Japanse komaf – leeftijd 18 ...
    (Date:7/30/2014)... , July 30, 2014  Cepheid (Nasdaq: ... group purchasing contract with Premier will end on ... Premier GPO will be able to continue their ... Baycare, HPA, MedAssets, Novation, and ROi, in addition ... directly with Cepheid. "Cepheid has always ...
    (Date:7/30/2014)... 2014 The Board of Directors of ... evening expressed support for the "Pharmacists, Patient Care ... Pharmacy Practitioners (JCPP).  As a JCPP member, AMCP ... period to develop a scalable, viable and consistent ... "Pharmacists are fast becoming one of the most ...
    Breaking Medicine Technology:Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2
    ... Reportlinker.com announces that a new market ... Commercial Insight: Antihormonal Cancer ... generic sales erosion ... therapies are a class of drugs used ...
    ... NEW YORK, Nov. 8, 2010 Reportlinker.com ... is available in its catalogue: ... for optimizing growth in key regions and ... The flurry of recent ...
    Cached Medicine Technology:Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 2Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 3Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 4Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 5Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 6Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 7Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 8Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 9Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 2Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 3Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 4Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 5Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 6Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 7
    (Date:7/31/2014)... CITY, Mo. (PRWEB) July 31, 2014 ... of highly experienced, sub-specialty trained neurosurgeons at the ... of the Spine Program and director of spine surgery. ... in Richland, Wash. , “Dr. Upadhyaya has been recognized ... invasive and complex spine issues. His addition to the ...
    (Date:7/31/2014)... Recognizing that today’s medical students are tomorrow’s ... announced today its student discount program. ... a healthcare-related field, as well as medical residents in ... the conference, scheduled for September 17-20, 2014 in San ... , “As a future Registered Dietitian, I’m excited ...
    (Date:7/31/2014)... 2014 When it comes to aesthetics ... and improve. As such, Natalie Sharp's Pure Vitality ... for a new, more focused direction and to provide ... patients! , Pure Vitality Rx is Oyster Bay's premier ... wide variety of services primarily dedicated to women. Services ...
    (Date:7/31/2014)... (August 1, 2014) While it is known that members ... use alcohol, a new study finds that female enlistees ... than their civilian counterparts. This study was published today ... journal published on behalf of the Inter-University Seminar on ... and Lucky Tedrow studied surveys of nearly 9,000 men ...
    (Date:7/31/2014)... July 31, 2014 Sales in the organic ... to 2014, according to radio talk show host Sharon Kleyne, ... rapid growth since 1990. The US economy in the same ... Power of Water radio show, reported this information following a ... a worldwide manufacturer of organic and natural food products. ...
    Breaking Medicine News(10 mins):Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 2Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 4Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 3Health News:Natalie Sharp's Pure Vitality Rx Upgrade - Partnership With Shangri-La Spa and Website Facelift! 2Health News:Women in military less likely to drink than civilian women 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3
    ... Synovics,Pharmaceuticals, Inc. (OTC Bulletin Board: SYVC), a ... Gange, has been,appointed Principal Executive Officer of ... responsibility of overseeing all executive functions. Mr. ... of directors and is the Chief,Financial Officer ...
    ... Nationwide,Health Properties, Inc. (NYSE: NHP ) today ... President, Tax. Mr. Laty had previously been the,Vice President, ... had,over eight years experience with a "Big 4" accounting ... Estate Investment Trusts. Mr. Laty is,a graduate of California ...
    ... do find 11 anti-seizure drugs heighten suicide risk, and ... 10 (HealthDay News) -- Anti-seizure drugs can cause ... warrant the government,s strongest warning label on them, a ... 20-member panel voted unanimously, with one abstention, to back ...
    ... of Mental Health estimates that in any given year, ... from some form of anxiety disorder, including debilitating conditions ... (PTSD). It is estimated that nearly 15 percent ... PTSD, underscoring the urgency to develop better treatment strategies ...
    ... trials, design may also mask risk of HIV drug resistance ... study questions whether vaginal microbicides being developed to help protect ... from the virus that causes AIDS. , The study, ... of the National Academy of Sciences , also shows that, ...
    ... anti-seizure drugs that showed double the risk , , THURSDAY, ... cause increased suicidal tendencies in patients, a U.S. health ... experts voted unanimously to back the findings on 11 ... Administration, the Associated Press reported. , In ...
    Cached Medicine News:Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 2Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 3Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 4Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 5Health News:FDA Advisers Don't Back Epilepsy Drug Warnings 2Health News:Rutgers research identifies brain cells related to fear 2Health News:Rutgers research identifies brain cells related to fear 3Health News:Vaginal Microbicides Might Help More Men Than Women 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 3
    ... As a prophylaxis for deep vein ... effective combination of graduated sequential compression and ... thrombus formation by increasing venous ejection while ... VenaFlow System includes a pump with tube ...
    ... Full Transportability: Innovative design allows the ... in for therapy or when to ... Choose the prophylactic method to deliver ... both simultaneously. ,Automatic Garment Detection: Automatically ...
    ... boot specially lasted for fiberglass casts... ... sole for easy ambulation! ,The SlimLine ... last so it fits better than ... with our stretchable upper, a custom ...
    The Low Profile boot provides a durable canvas upper, with an open toe and heel. Padded EVA insole protection. The lower outsole compensates for casting thickness. Available in six unisex sizes....
    Medicine Products: